Indicated for: acute promyelocytic leukemia
Route of administration: infusion
Substance: arsenic trioxide (antineoplastic agent)
ATC: L01XX27 (Antineoplastic and immunomodulating agents | Other antineoplastic agents)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Arsenic trioxide is a medication used in the treatment of acute promyelocytic leukemia (APL), a rare form of leukemia. It works by inducing apoptosis (programmed cell death) in cancer cells and promoting their differentiation into normal cells.
Arsenic trioxide is administered intravenously, usually as part of a combination regimen with other medications such as all-trans retinoic acid (ATRA). It is commonly used in cases of relapsed or refractory APL, as well as a first-line therapy in certain situations.
Common side effects include nausea, fatigue, fever, and elevated liver enzymes. In rare cases, severe complications such as differentiation syndrome or cardiac arrhythmias may occur.
Arsenic trioxide is an essential medication in the treatment of acute promyelocytic leukemia, helping to improve survival rates and patient outcomes.